The bioengineered protein drugs market is experiencing a paradigm shift, with pharmaceutical and biotech companies leveraging advanced biopharmaceuti ...

Global Phase 3 TRANSCEND study will evaluate the efficacy and safety of felzartamab, as compared to placebo, in adults with late AMRAMR is a ...

But I think we have great teams within Biogen and we are able to really dissect ... we've seen a robust reduction of the MAPT mRNA or tau protein levels in brain regions where BIIB080 was detected.

CervoMed's stock soars 400% on promising dementia drug data. See more on insights, potential concerns, and what it means for ...

Cambridge, Massachusetts Thursday, March 13, 2025, 10:00 Hrs [IST] ...

March 11, 2025 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB ... Felzartamab is an investigational therapeutic human monoclonal antibody directed against CD38, a protein expressed on mature plasma ...

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing ...

MorphoSys will earn a one-time milestone payment of $35 million from Biogen. Felzartamab is an investigational therapeutic human monoclonal antibody directed against CD38, a protein expressed on ...

Meanwhile, Biogen also reported data from a long-term ... and also cut plasma levels of a biomarker protein called p-tau181 at week 128, according to a presentation of the data at the ...

Biogen has made a further push into RNA-based ... which is used as a template for protein synthesis in cells – is transformed into a mature form. As its name suggests, splicing involves snipping ...